Pompano Beach, FL, April 14th, 2020 — BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), and a certified full-service GMP contract development and manufacturing organization, with a focus in perinatal tissue-based medical products, today announced that it had launched a new website at www.BioStemLifeSciences.com.
This new website provides detailed information about the capabilities of the company as a Contract Development and Manufacturing Organization (CDMO), as well as aligning with the company’s brand identity. Since introducing its Contract Development and Manufacturing division earlier this year, BioStem Life Sciences has garnered an impressive uptick in potential partnership inquiries. The new website helps to better convey their capabilities, not just in development and production, but in Quality and Regulatory as well.
“Since launching our GMP Contract Development and Manufacturing (CDMO) division earlier this year and receiving a large amount of interest in our abilities, it was imperative to bring our digital presence up to date and showcase the capabilities of the lab and our scientific team” said Matthew Wurm, Director of Marketing for BioStem Life Sciences.
About BioStem Life Sciences, Inc.
A company focused on the development of the highest quality birth tissue products for multiple sectors of healthcare. BioStem Life Sciences also provides leading class contract development and manufacturing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to commercialization. For the latest news and information about BioStem Life Sciences and its brands, please visit www.biostemlifesciences.com
About BioStem Technologies, Inc. (OTC PINK: BSEM)
BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The company’s mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, OROPRO™ VENDAJE™ and VENDAJE™ OPTIC. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
Andrew Van Vurst
info@biostemtech.com
(954) 380-8342